Articles Vol. 67 No. 7 26/07/2026

SERUM PEPSINOGEN LEVELS AND THEIR ASSOCIATION WITH CLINICOPATHOLOGICAL FEATURES OF CHRONIC GASTRITIS WITH HELICOBACTER PYLORI INFECTION

Nguyen Trong Phuong1,2, Thai Thi Hong Nhung1,2
1 Can Tho University of Medicine and Pharmacy
2 Trường Đại học Y Dược Cần Thơ
DOI: 10.52163/yhc.v67i7.5893
27 Views
0 Downloads
Keywords
Chronic gastritis, serum pepsinogen, Helicobacter pylori.
Abstract

Objective: To investigate serum pepsinogen levels and their associations with histopathological features in patients with chronic gastritis and Helicobacter pylori infection.

Subject and methods: This analytical cross-sectional study included 59 patients with chronic gastritis and H.pylori infection at 30-4 Hospital from June 2025 to January 2026. Serum pepsinogen I and pepsinogen II levels were measured by ELISA and the pepsinogen I/II ratio was calculated. These indices were compared according to the degree of mucosal damage, inflammatory activity and intestinal metaplasia.

Results: The mean age of the patients was 46.1 ± 16.4 years, and 52.5% were female. The median serum pepsinogen I level, serum pepsinogen II level, and pepsinogen I/II ratio were 66.7 ng/ml, 18.9 ng/ml and 3.5, respectively. The pepsinogen I/II ratio was significantly lower in patients with active gastritis and those with intestinal metaplasia. No statistically significant differences were observed in serum pepsinogen I or pepsinogen II levels across histopathological features. The pepsinogen I/II ratio showed discriminatory ability for active gastritis and intestinal metaplasia, with areas under the curve of 0.85 and 0.723, respectively.

Conclusion: The pepsinogen I/II ratio may serve as a noninvasive serum biomarker for assessing inflammatory activity and precancerous gastric lesions in patients with chronic gastritis and H.pylori infection.

References
[1]
Ferlay J, Ervik M, Lam F, Laversanne M, Colombet M, Mery L et al. Global cancer observatory: cancer today (version 1.1), 2024. https://gco.iarc.fr/en. Google Scholar
[2]
Quach D.T, Mai B.H, Tran M.K, Dao L.V, Tran H.V, Vu K.T et al. Vietnam Association of Gastroenterology (VNAGE) consensus on the management of Helicobacter pylori infection. Frontiers in medicine, 2022, 9: 1065045. doi: 10.3389/fmed.2022.1065045. Google Scholar
[3]
Butt J, Epplein M. How do global trends in Helicobacter pylori prevalence inform prevention planning? The Lancet Gastroenterology & Hepatology, 2023, 8 (6): 498-9. doi: 10.1016/s2468-1253(23)00101-2. Google Scholar
[4]
Codolo G, Coletta S, D’Elios M.M, de Bernard M. HP-NAP of Helicobacter pylori: the power of the immunomodulation. Front Immunol, 2022, 13: 944139. doi: 10.3389/fimmu.2022.944139. Google Scholar
[5]
Qin Y, Geng J.X, Huang B. Clinical value of serum pepsinogen in the diagnosis and treatment of gastric diseases. World J Gastrointest Oncol, 2023, 15 (7): 1174-81. doi: 10.4251/wjgo.v15.i7.1174. Google Scholar
[6]
Dinis-Ribeiro M, da Costa-Pereira A, Lopes C, Barbosa J, Guilherme M, Moreira-Dias L et al. Validity of serum pepsinogen I/II ratio for the diagnosis of gastric epithelial dysplasia and intestinal metaplasia during the follow-up of patients at risk for intestinal-type gastric adenocarcinoma. Neoplasia, 2004, 6 (5): 449-56. doi: 10.1593/neo.03505. Google Scholar
[7]
Bùi Chí Nam, Vũ Văn Khiên, Phan Quốc Hoàn. Nghiên cứu mối liên quan giữa nồng độ pepsinogen, gastrin huyết thanh và tổn thương mô bệnh học viêm dạ dày mạn. Tạp chí Y học Việt Nam, 2024, 544 (1): 369-73. doi: 10.51298/vmj.v544i1.11773. Google Scholar
[8]
Stolte M, Meining A. The updated Sydney system: classification and grading of gastritis as the basis of diagnosis and treatment. Can J Gastroenterol, 2001, 15 (9): 591-8. doi: 10.1155/2001/367832. Google Scholar
[9]
Vaira D, Gatta L, Ricci C, D’Anna L, Miglioli M. Helicobacter pylori: diseases, tests and treatment. Digestive and Liver Disease, 2001, 33 (9): 788-94. doi: 10.1016/S1590-8658(01)80697-6. Google Scholar
[10]
Đặng Ngọc Quý Huệ. Nghiên cứu tỷ lệ kháng Clarithromycin, Levofloxacin của Helicobacter pylori bằng Epsilometer và hiệu quả của phác đồ EBMT ở bệnh nhân viêm dạ dày mạn. Luận án tiến sĩ y học, Trường Đại học Y Dược, Đại học Huế, 2018. Google Scholar
[11]
Sánchez-López J.Y, Díaz-Herrera L.C, Rizo-de la Torre L.D.C. Pepsinogen I, pepsinogen II, gastrin-17, and Helicobacter pylori serological biomarkers in the diagnosis of precursor lesions of gastric cancer. Archives of medical science: AMS, 2024, 20 (3): 1016-21. doi: 10.5114/aoms/189971. Google Scholar
[12]
Kitahara F, Kobayashi K, Sato T, Kojima Y, Araki T, Fujino M.A. Accuracy of screening for gastric cancer using serum pepsinogen concentrations. Gut, 1999, 44 (5): 693-7. doi: 10.1136/gut.44.5.693. Google Scholar
[13]
Xia J, Liu Z, Zhang K. Pepsinogen serology and gastritis OLGA staging in mucosal atrophy assessment: a cross-sectional study involving East China endoscopy population. Gastroenterology Research and Practice, 2020: 2324505. doi: 10.1155/2020/2324505. Google Scholar
[14]
Lim S.H, Kim N, Choi Y, Choi J.M, Han Y.M, Kwak M.S et al. Assessing serum pepsinogen and Helicobacter pylori tests for detecting diffuse-type gastric cancer: insights from a large-scale and propensity-score-matched study in Republic of Korea. Cancers, 2025, 17 (6): 955. doi: 10.3390/cancers17060955. Google Scholar